Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

When is it safe to schedule an allo-HSCT after COVID-19 infection?

During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

How does COVID-19 affect outcomes in AML?

During the EHA2021 Virtual Congress, the AML Hub spoke with Olga Gavrilina, National Research Center for Hematology, Moscow, RU. We asked, How does COVID-19...

COVID-19 vaccination for hematopoietic stem cell transplant patients

The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...

Standardizing next-generation sequencing MRD assessment in AML

Detection of measurable residual disease (MRD) is recommended for the evaluation of treatment response in patients with acute myeloid...

Germline mutations in patients with hematologic malignancies

Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...

FDA grants orphan drug designation to eprenetapopt for TP53-mutated AML

Very recently, eprenetapopt (APR-246), a small molecule that reactivates mutant and inactivated p53 protein, was granted orphan...

Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

RVU120, a CDK8 inhibitor for the treatment of anemia in MDS and AML

The symptom burden of anemia is considerable for patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and...

FDA has granted breakthrough therapy designation to venetoclax in combination with azacitidine for MDS

On July 21, 2021, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy...

SNDX-5613 shows encouraging overall response rate in relapsed/refractory acute leukemias

SNDX-5613, a potent, highly selective, oral inhibitor of the menin-mixed lineage leukemia (MLL) binding...

FDA approves extended indication of daunorubicin plus cytarabine to include pediatric patients with AML

On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

Quantifying patient and physician preferences in post-HSCT maintenance treatment of AML

Hematopoietic stem cell transplant (HSCT) in patients with acute myeloid leukemia (AML) is often followed by...

RVU120, a CDK8 inhibitor for the treatment of anemia in MDS and AML

The symptom burden of anemia is considerable for patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and...

Standardizing next-generation sequencing MRD assessment in AML

Detection of measurable residual disease (MRD) is recommended for the evaluation of treatment response in patients with acute myeloid...